| 1  | Quantifying the effects of  |
|----|---|
| 2  | non-pharmaceutical and pharmaceutical   |
| 3  | interventions against COVID-19 epidemic in  |
| 4  | the Republic of Korea: Mathematical   |
| 5  | model-based approach considering age  |
| 6  | groups and the Delta variant  |
| 7  | Youngsuk Ko <sup>1</sup> , Victoria May P. Mendoza <sup>1</sup> , Yubin Seo <sup>2</sup> , Jacob        |
| 8  | Lee <sup>2</sup> , Yeonju Kim <sup>3</sup> , Donghyok Kwon <sup>3</sup> , and Eunok Jung <sup>1,*</sup> |
| 9  | <sup>1</sup> Department of Mathematics, Konkuk University   |
| 10 | <sup>2</sup> Division of Infectious Disease, Department of Internal                                     |
| 11 | Medicine, Kangnam Sacred Heart Hospital, Hallym University  |
| 12 | College of Medicine   |
| 13 | <sup>3</sup> Division of Public Health Emergency Response Research, Korea                               |
| 14 | Disease Control and Prevention Agency   |
| 15 | *Corresponding author   |
| 16 | **Word count: 3186  |
|    |   |

1

| 17 | Abstract  |
|----|---|
| 18 | Background:   |
| 19 | Early vaccination efforts and non-pharmaceutical interventions were in-       |
| 20 | sufficient to prevent a surge of coronavirus disease 2019 (COVID-19) cases    |
| 21 | triggered by the Delta variant. This study aims to understand how vaccina-    |
| 22 | tion and variants contribute to the spread of COVID-19 so that appropriate    |
| 23 | measures are implemented.   |
| 24 | Methods:  |
| 25 | A compartment model that includes age, vaccination, and infection with        |
| 26 | the Delta or non-Delta variants was developed. We estimated the trans-        |
| 27 | mission rates using maximum likelihood estimation and phase-dependent         |
| 28 | reduction effect of non-pharmaceutical interventions (NPIs) according to      |
| 29 | government policies from 26 February to 8 October 2021. We extended           |
| 30 | our model simulation until 31 December considering the initiation of eased    |
| 31 | NPIs. Furthermore, we also performed simulations to examine the effect of     |
| 32 | NPIs, arrival timing of Delta variant, and speed of vaccine administration.   |
| 33 | Results:  |
| 34 | The estimated transmission rate matrices show distinct pattern, with the      |
| 35 | transmission rates of younger age groups (0 39 years) much larger than        |
| 36 | non-Delta. Social distancing (SD) level 2 and SD4 in Korea were associated    |
| 37 | with transmission reduction factors of 0.64 to 0.69 and 0.70 to 0.78, respec- |
| 38 | tively. The easing of NPIs to a level comparable to SD2 should be initiated   |
| 39 | not earlier than 16 October to keep the number of severe cases below the      |
| 40 | capacity of Korea's healthcare system. Simulation results also showed that    |
| 41 | a surge prompted by the spread of the Delta variant can be prevented if the   |
| 42 | number of people vaccinated daily was larger.                                 |
| 43 | Conclusions:  |
| 44 | Simulations showed that the timing of easing and intensity of NPIs, vacci-    |
| 45 | nation speed, and screening measures are key factors in preventing another    |
| 46 | epidemic wave.  |

# 47 **1 Keywords**

- 48 COVID-19, Delta variant, mathematical model, maximum likelihood estima-
- 49 tion, age-structure, vaccination, non-pharmaceutical interventions, Korea, so-
- 50 cial distancing

# 51 2 Key Messages

- Maximum likelihood estimation can be utilized to determine the transmission rates of the Delta and non-Delta variants.
- The phase-dependent NPIs implemented by the Korean government were
   effectively quantified in the modelling study.
- Even with fast vaccination, resurgence of cases is still possible if NPIs are
   eased too early or screening measures are relaxed.
- The model can be used as a guide for policy makers on deciding appro-
- <sup>59</sup> priate SD level that considers not only disease control, but also the socio-
- 60 economic impact of maintaining strict measures.

### **3** Introduction

The coronavirus disease 2019 (COVID-19) is an ongoing pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The rise in the number of COVID-19 cases observed worldwide since July 2021 can be attributed to the emergence of the Delta variant of SARS-CoV-2 [1]. The Delta variant significantly reduced the effectiveness of vaccines to symptomatic infection to about 50-70% compared to the Alpha variant [2, 3]. Nevertheless, these vaccines are reported to still be effective against severe disease, hospitalization, and death [2, 4].

To mitigate the spread of COVID-19, on top of vaccination, various non-70 pharmaceutical interventions (NPIs), such as social distancing (SD), are still 71 implemented concurrently. In Korea, a four-level SD plan has been imple-72 mented since July 2021. The plan outlines the number of persons allowed in a 73 gathering and operational guidelines of shops, restaurants, gyms, pubs, con-74 cert halls, sports stadium, and other commercial facilities. Since 12 July 2021, 75 SD level has been raised to the highest (SD4) to combat the fourth wave of 76 COVID-19 in the Republic of Korea. As of 29 October 2021, there are 360 536 77 confirmed cases and 2817 deaths of COVID-19 in Korea [5]. 78

Vaccination in Korea began on 26 February 2021 and priority was given to 79 the healthcare workers and elderly. The vaccination plan proceeded according 80 to age, starting with older age group [5]. Several types of vaccines have been 81 administered, mostly BNT162b2 or ChAdOx1 [5]. Meanwhile, the first case of 82 a local community transmission in Korea with the Delta variant was reported 83 on 27 April 2021. The number of cases has steeply increased since then and the 84 proportion of the Delta variant is almost 100% among the genome-sequenced 85 COVID-19 cases in Korea [6]. 86



Transmission rates between age groups before and during the period when

> Delta became the dominant variant of SARS-CoV-2 infections are estimated 88 using MLE, which is a preferred parameter estimation and inference tool in 89 statistics [7, 8]. The key factors leading the epidemic of COVID-19 recently 90 are vaccination, variants of the virus, and implementation of SD. In this study, 91 we developed an age-structured compartment model that captures COVID-19 92 transmission with the Delta and non-Delta variants among vaccinated and un-93 vaccinated people. Furthermore, we quantify NPIs according to government 94 policy and present scenarios that investigate the impact of timely vaccination, 95 effective NPIs, and early detection of cases. 96

### **97 4** Materials and Methods

### 98 4.1 Data

<sup>99</sup> We analyzed the COVID-19 case data including age, date of diagnosis by PCR <sup>100</sup> test, and date of symptom onset from 26 February to 10 September 2021 pro-<sup>101</sup> vided by the Korea Disease Control and Prevention Agency (KDCA). The data <sup>102</sup> on the number of people vaccinated per day, type of vaccine, and age of the <sup>103</sup> person who were vaccinated from 26 February to 8 October 2021 are available <sup>104</sup> in [9].

### **4.2** Mathematical model

The model we develop is an extension of the models in [7, 8] to include age-106 specific transmission rates of the Delta and non-Delta variants. The dynamics 107 of infection with the Delta or non-Delta variants follows an SEIQR scheme, 108 where the subscripts *i* and *v* refer to age group and vaccination, respectively, 109 and the superscripts *non* $\delta$  or  $\delta$  refer to whether the infection is with the non-110 Delta or Delta variant, respectively. Eight age groups are considered: 0 to 17 111 are referred to as group 1, 18 to 29 as group 2, and those aged 30 to 39, 40 to 49, 112 and so on until 80 and above, are groups 3 to 8. The model diagram depicted in 113 Figure 1 shows that susceptible (S) and vaccinated individuals may be exposed 114 to non-Delta or Delta variants (*E*), with a force of infection  $\lambda$ , and become in-115 fectious (1). Once confirmed, these individuals are isolated and categorized as 116 mild  $(Q^m)$  or severe  $(Q^s)$ , and eventually recover (R) or die. Compartments 117 for individuals who are vaccinated effectively (V), ineffectively (U), and then 118 developed partial ( $P^{part}$ ) or full immunity ( $P^{full}$ ) are also considered. 119

The age-specific, vaccine-dependent parameters  $e^{part}$ ,  $e^{full}$ , and  $\omega$  consider the proportion of an age group vaccinated with either ChAdOx1 or BNT162b2



Figure 1: The model flowchart describing the transmission of COVID-19 with the non-Delta or Delta variants. The susceptible class of age group *i*, denoted by  $S_i$ , can be exposed to the non-Delta or Delta variants  $(E_i^{non\delta}, E_i^{\delta})$  with forces of infection  $\lambda_i^{non\delta}$  or  $\lambda_i^{\delta}$ , respectively. The transmission reduction factor  $\mu(t)$ quantifies the NPIs according to government policy. Also, S<sub>i</sub> can become effectively  $V_i$  or ineffectively  $U_i$  vaccinated, depending on the daily number of vaccinated individuals  $v_i$ , and vaccine effectiveness to the non-Delta variant  $e_i^{part}$ . Individuals in  $V_i$  become partially  $P_i^{part}$  or fully protected  $P_i^{full}$  from infection after  $1/\omega_i$  days on average, or may be exposed to the non-Delta or Delta variant  $(E_{i,v}^{non\delta}, E_{i,v}^{\delta})$ . Vaccine effectiveness to the Delta variant is denoted by  $e_i^{full}$ . The mean latent period of the non-Delta and Delta variants are  $1/\kappa^{non\delta}$  and  $1/\kappa^{\delta}$  days, respectively. The mean infectious period is  $1/\alpha$  days. Those in the infectious classes  $(I_i^{non\delta}, I_i^{\delta}, I_{i,v}^{non\delta})$  and  $I_{i,v}^{non\delta})$  are isolated as soon as confirmed, and are classified as mild  $(Q_i^m, Q_{i,v}^m)$  or severe  $(Q_i^s, Q_{i,v}^s)$ . Individuals in the isolated compartments may die or recover  $(R_i)$  after  $1/\gamma$  days on average. The parameters  $p_i$ ,  $p_{i,v}$  represent the proportion that becomes severe and  $f_i$ ,  $f_{i,v}$  are the mean fatality rates of the unvaccinated and vaccinated individuals, respectively.

<sup>122</sup> [10], effectiveness of these vaccines to the Delta and non-Delta variants [3], <sup>123</sup> and interval between doses [11]. The transmission rates  $\beta$  for the Delta and <sup>124</sup> non-Delta variants are estimated using MLE. The transmission reduction fac-<sup>125</sup> tor  $\mu(t)$ , which quantifies the NPIs according to government policy, is also es-<sup>126</sup> timated. The values of  $\nu$ , p and f are derived from data. Details of the model

<sup>127</sup> development are found in Appendix A.

We apply MLE to estimate the transmission rates of the Delta and non-Delta variants between age groups by considering two periods. Transmission rates of the non-Delta variant were estimated from the period 26 February to 30 June 2021, while the data from 1 August to 10 September, when the proportion of cases with the Delta variant was over 80%, were used to estimate the transmission rates for the Delta variant [12].

### 134 4.3 Modelling scenarios

To examine the impact of vaccination rollout, we extended the model simula-135 tion until 30 December 2021 and analyzed the effect of easing NPIs at different 136 times. Considering that approximately 77% of the population already have 137 at least one dose, we assumed that 85% of the population is vaccinated by 30 138 November 2021. We consider three dates for the initiation of eased NPIs: 8 139 October, 18 October, and 1 November. For each date, we simulate three scenar-140 ios with different values of the transmission reduction factor  $\mu(t)$ :  $\mu = 0.69$  in 141 scenario 1 (S1),  $\mu = 0.64$  in scenario 2 (S2), and  $\mu = 0.52$  in scenario 3 (S3). The 142 estimated value obtained from 16 April to 3 June 2021 is S1, and the minimum 143 value estimated in this study is S2 (from 16 June to 11 July 2021). The value of 144  $\mu$  in S3 was estimated from the third epidemic wave in 2020, when it was SD1, 145 and is a relatively lower value compared to S2 [13]. 146

<sup>147</sup>We also proceeded with simulation-based experiment to study the effects <sup>148</sup>of varying the speed of vaccination, arrival timing of the Delta variant, and in-<sup>149</sup>tensity of NPIs. In this case, the initial condition of simulations is identical to <sup>150</sup>26 February 2021 in Korea and the simulation time is set to 365 days. The total <sup>151</sup>number of vaccinated people is assumed to be 40 million, which is approxi-<sup>152</sup>mately 78% of the population in Korea, and the number of people vaccinated

daily is set to 150 000, 200 000, or 400 000. Moreover, we fix the order of vac-

- cination from oldest to youngest, that is, 8-7-6-5-4-3-2, excluding group 1. We
- denote by  $t_{\delta}$  the day when the individuals exposed to the Delta variant arrived
- <sup>156</sup> in the local community, and we set its range from zero to 80 days. Note that
- in Korea, the date of arrival of the Delta variant corresponds to  $t_{\delta}$  = 52. We
- consider values of  $\mu$  from 0.52 to 0.78 in 0.001 increments. In total, there are 21
- <sup>159</sup> 141 simulations for the different values of  $\nu_i$ ,  $t_{\delta}$ , and  $\mu$ .

### 160 5 Results

### <sup>161</sup> 5.1 Parameter Estimation

The estimated transmission rates obtained using MLE form a matrix according to the age groups. The transmission rate matrices, visualized in Figure 2, represent the transmission patterns of the non-Delta (a) and Delta variants (b) in Korea.



Figure 2: Estimated transmission rates among age groups (a) non-Delta variants from 26 February to 30 June 2021 and (b) Delta variant from 1 August to 10 September 2021.

Since the various government policies including SD implemented during
 the periods considered in estimating the transmission rates, we normalize the
 transmission rate matrices to exclude phase-dependent factors. The details of
 the computation are found in Appendix C.

We use the normalized transmission rate matrices in estimating the factor  $\mu(t)$ , which represents the reduction in transmission induced by NPIs according to government policy. Table 1 presents the estimates for each phase from 26 February to 8 October 2021. Figure 3 (a) shows the plots of the estimates for the reduction factor  $\mu(t)$  (red curve) with the effective reproductive num-

> ber ( $\mathcal{R}_t$ , blue curve) described in Appendix C. At the start of the simulation 175 period, Seoul Capital Area was at SD2. When  $\mu(t)$  increased from 0.64 to 0.69 176 around 16 April 2021,  $\mathcal{R}_t$  decreased to 0.97 and stayed below 1 until around 16 177 June. From 16 June to 11 July,  $\mu$  was estimated at 0.64 and  $\mathcal{R}_t$  jumped to as high 178 as 1.52. The exponential rise in the proportion of cases infected with the Delta 179 variant (black solid curve in Figure 3 (a)) and daily confirmed cases (Figure 3 180 (b)) was also observed on the same period, which prompted the start of the 181 fourth wave. On 12 July, the Korean government raised the SD level in Seoul 182 Capital Area to SD4. A steep increase in the cumulative confirmed cases was 183 seen beginning 12 July (Figure 3 (c)), and the estimates for  $\mu$  were the highest 184 from this period until 06 September. At the same time, the proportion of hosts 185 having full immunity (black dashed curve in Figure 3 (a)) increased steadily, 186 reaching up to about 50% by the end of the estimation period. On the last 187 phase, the estimated value of  $\mu$  was 0.70. 188

| Phase | Period           | Value | SD Level | $\mathcal{R}_{t}$ |
|-------|------------------|-------|----------|-------------------|
| 1     | 26 Feb to 25 Mar | 0.64  | 2        | [1.13, 1.14]      |
| 2     | 26 Mar to 15 Apr | 0.65  | 2        | [1.11, 1.12]      |
| 3     | 16 Apr to 3 Jun  | 0.69  | 2        | [0.96, 0.97]      |
| 4     | 4 Jun to 15 Jun  | 0.70  | 2        | [0.94, 0.96]      |
| 5     | 16 Jun to 11 Jul | 0.64  | 2        | [1.16, 1.52]      |
| 6     | 12 Jul to 25 Jul | 0.76  | 4        | [1.03, 1.09]      |
| 7     | 26 Jul to 8 Aug  | 0.77  | 4        | [1.07, 1.07]      |
| 8     | 9 Aug to 5 Sep   | 0.78  | 4        | [0.91, 1.00]      |
| 9     | 6 Sep to 19 Sep  | 0.71  | 4        | [1.11, 1.21]      |
| 10    | 20 Sep to 8 Oct  | 0.70  | 4        | [0.94, 1.10]      |

Table 1: Estimates for the phase-dependent, transmission reduction factor  $\mu(t)$ , social distancing (SD) level, and range of effective reproductive number  $\mathcal{R}_t$  from 26 February to 8 October 2021.

To illustrate how  $\mu$  can be used to suggest appropriate SD level, assume

> that the basic reproductive number of the disease is five, Delta and non-Delta 190 variants can infect the population, 80% of population is vaccinated, and vac-191 cine effectiveness is 62.5%. Then without NPIs,  $\mathcal{R}_t = 5 \times 0.8 \times 0.625 = 2.5$ . To 192 maintain an  $\mathcal{R}_t$  below one, SD2 is appropriate since the minimum estimated 193 value of  $\mu(t)$  on SD2 was 0.64 and this translates to  $\mathcal{R}_t = (1 - 0.64) \times 2.5 = 0.9$ . 194 On the other hand if  $\mu = 0.52$ , which represents worst case during SD1, then 195  $\mathcal{R}_t = (1-0.52) imes 2.5 = 1.2$ . In this case, SD4 may not necessary and can 196 aggravate present economic problems. 197

> In Figure 4, we present the best fit of the model to the data on daily and 198 cumulative cases per age group. The rise in the number of cases in the period 199 from 16 June 2021 was observed across all age groups, with age 18-29 having 200 the most and the elderly groups having the least increase. The model shows a 201 peak (459 cases) on 16 August and another peak (519 cases) on 28 September 202 in age 18-29. Towards the end of the simulation period, a decreasing trend 203 in the number of cases was observed in most age groups except age 0-17, not 204 vaccinated. 205

### <sup>206</sup> 5.2 Analysis on the timing of easing the NPIs

Nine scenarios considering different dates of initiation and levels of eased NPIs 207 are displayed in Figure 5. The red, black, and blue curves, correspond to start-20 ing the eased NPIs on 8 October, 18 October, and 1 November 2021, respec-209 tively. The solid curves represent S1, dashed curves S2, and dotted curves S3. 210 Panel (a) shows  $\mathcal{R}_t$ , (b) the daily confirmed cases, (c) the number of severe 211 patients requiring hospital beds, and (d) the cumulative death. The dashed 212 grey curve in panel (c) marks the maximum number of hospital beds (1067) for 213 severe patients in Korea [14]. Results show that the worst case scenario is S3 214 with 8 October as easing time, wherein the peak number of daily cases, severe 215



Figure 3: The parameter estimation results obtained by fitting the model to the cumulative confirmed cases. Panel (a) shows the effective reproductive number (blue), estimates of the transmission reduction factor  $\mu(t)$  (red), proportion of the active cases infected with the Delta variant (black solid curve), and proportion of the total population who has immunity (black dashed curve). Panel (b) shows the best fit of the model to the daily confirmed cases and (c) the best fit of the model to the cumulative cases from 26 February to 8 October 2021.

patients, and cumulative deaths could reach 8207, 1617, and 6528, respectively.
But if the easing to S3 was started later, on 18 October or 1 November, the peak
numbers could be reduced to 4385 (40.48% reduction) or 1961 (76.11% reduction) for the peak daily cases, 879 (45.64% reduction) or no increase for the peak



Figure 4: The best fit of the model to the (a) daily confirmed cases and (b) cumulative confirmed cases per age group. The boxes represent the data per age group from 26 February to 10 September 2021.

number of severe patients, and 3847 (42.07% reduction) or 2313 (64.57% reduction) for the cumulative deaths, compared to when the easing was initiated
earlier. The rest of the simulations show a decreasing trend of daily confirmed
cases and number of severe patients. The simulations illustrate the importance
of the timing of easing NPIs in preventing the occurrence of another epidemic
wave. All scenarios, except the worst case, show that the number of severe
patients did not reach the limit (1067) of Korea.



Figure 5: Results on the effect of easing NPIs at different times. Panel (a) shows the effective reproductive number, (b) number of daily confirmed cases, (c) number of severe patients requiring hospital beds, and (d) cumulative number of deaths. Colours and shapes of curves indicate the timing of initiation (8 October, 18 October, and 1 November) and level of eased NPIs (S1, S2, and S3). Grey dashed line in (c) indicates the number of available beds (1067) for severe patients in Korea.

# <sup>227</sup> 5.3 Analysis on the vaccination speed, NPIs, and arrival tim-

### ing of the Delta variant

Figure 6 displays the simulation results when  $\mu = 0.67$ ,  $t_{\delta} = 52$ , and  $\nu_i =$ 229 200 000 or 400 000. In panel (a),  $\mathcal{R}_t$  and the proportion of cases infected with 230 the Delta variant are displayed. The magenta asterisk indicates  $t_{\delta} = 52$ . When 231  $v_i = 200\,000, \,\mathcal{R}_t$  increased up to 1.4, while if  $v_i = 400\,000, \,\mathcal{R}_t$  decreased to 232 below one. In panels (b) and (c), a second peak with more than 2000 cases 233 and 600 severe patients is observed when  $v_i = 200\,000$  (red curve), whereas no 234 second peak is observed when  $v_i = 400\,000$  (blue curve). Panel (d) shows that 235 the cumulative deaths when  $v_i = 200\,000$  can reach 4.48 times higher compared 236 to when  $v_i = 400\,000$ . Panels (e) and (f) display the cumulative number of cases 237 and deaths of each age group, with 34% of the cases occurring in age group 2 238 and 68% of the deaths occurring in age group 8 when  $v_i = 200\,000$ . These 239 results highlight the effect of the daily number of vaccination to the occurrence 240 of another epidemic wave. 241

Figure 7 shows a heat map summarizing the results of the 21 141 simulations. The columns represent the daily vaccination number ( $v_i = 150\,000$ , 200 000, and 400 000) and the rows correspond to the number of confirmed cases, deaths, and peak number of severe patients requiring hospital beds. In each panel, the *x* axis represents  $t_{\delta}$  and the *y* axis corresponds to  $\mu$ . The dotted red curve in panels (g), (h), and (i) marks the maximum number of hospital beds (1067) for severe patients in Korea.



Figure 6: The simulation result with  $\mu = 0.67$ ,  $t_{\delta} = 52$ , and daily number of vaccination set to 200 000 or 400 000. Panel (a) shows the effective reproductive number, (b) number of daily confirmed cases, (c) number of severe patients requiring hospital beds, (d) cumulative number of deaths, (e) age-dependent number of confirmed cases, and (f) age-dependent number of deaths. Red and blue colours indicate that the number of daily administered vaccines is 200 000 and 400 000, respectively.



Figure 7: The simulation results of the 21,141 runs. The columns from left to right indicate the number of daily administered vaccines as 150 000, 200 000, and 400 000, respectively. Panels (a), (b), and (c) show the number of confirmed cases; (d),(e), and (f) the number of deaths; and (g),(h), and (i) the peak number of severe patients requiring hospital beds. Note that red dotted curve in panels (g),(h), and (i) indicates the maximum number of available beds (1067) for severe patients in Korea.

### 249 6 Discussion

The transmission rate matrix in this study was apparently different between 250 the Delta and non-Delta variants and by age groups. The transmission rate 251 with non-Delta variant was high between the same age groups. However, 252 transmission with the Delta variant was much higher among age groups of 253 18-29 and 30-39, and an increased transmission was observed between those 254 age groups and age groups of 50-59 and 60-69. This matrix reflects the distinct 255 epidemiologic characteristic of the COVID-19 epidemic after Delta became the 256 dominant variant of SARS-CoV-2 in Korea: 1) incidence in younger age groups, 257 those in 20s and 30s, increased; 2) and the major source of transmission moved 258 from group-related or institutional outbreaks to individual contacts [15, 16]. 259 These results indicate an increased transmission with Delta variant among 260 household contacts, which is coherent with previous studies [17, 18]. 261

Higher transmission rates with the Delta variant compared to the non-Delta 262 variant were also observed in the elderly groups, which may have resulted 263 from breakthrough infections in nursing homes and assisted living facilities 264 [27]. With the absence of vaccination, a much higher transmission rate with the 265 Delta variant was expected, but was not observed in the youngest age group 266 of 17 years old and below. This phenomenon was probably a consequence of 267 the Korean government policy on limiting the number of attendance in school to two-thirds since October 2020 [19]. According to the data, among all the 269 COVID-19 cases of those aged 17 years old and below in Korea, only about 270 15% are infected from schools during this period [20]. 271

We also analyzed the reduction in transmission induced by NPIs according to the government policy, presented by  $\mu(t)$ . SD2 and SD4 in Korea corresponded to  $\mu(t)$  values from 0.64 to 0.69, and from 0.70 to 0.78, respectively. Values of  $\mu(t)$  close to 0.7 may represent SD3 in Korea. Considering the ba-

> sic reproductive number of a disease, vaccine effectiveness, and the amount of administered vaccines, the fitted values of  $\mu(t)$  can be an effective measures of the government policy. This parameter would be informative to the healthcare professionals and policy makers on designing prevention and control measures for emerging or reemerging infectious diseases.

> Considering both the medical and economic impact of NPIs, the Korean 281 government plans to reduce SD, termed 'Back to normal or With-Corona', on 282 1 November 2021 [14]. Because vaccination and immunization takes time, we 283 explored the effect of delaying the initiation of eased SD in Figure 5. When 284 SD was eased to a minimal value (S3), no large-scale re-emergence of infec-285 tions was observed when S3 was delayed to 1 November, as opposed to when 286 it was initiated on 8 or 18 October. In other words, gradually easing NPIs 287 might be necessary when implementation is earlier. For example, in Korea, the 288 maximum number of people allowed in a private gathering after 6:00PM be-289 came four (ten for fully vaccinated) from two since 18 October, although SD 290 remained at SD4 [21]. 291

> In our generalized simulation on the effects of vaccination and NPIs, the 292 larger reduction of transmission factor  $(\mu(t))$  and faster vaccination rollout 293 or earlier implementation of stricter NPIs (e.g., expanding genomic testing to 294 people entering from high-risk countries or elevating SD) resulted in less inci-295 dence, severe cases, and deaths. We are aware that the supply of vaccines is not 296 enough globally, but fast administration of vaccines can block the occurrence 297 of another wave. In other words, epidemic can be controllable and stable if the 298 vaccination speed is faster. 29

> There are several limitations of this research. First, the contact pattern in the matrices was already affected by NPIs and might be not identical to the contact pattern before COVID-19, necessitating the normalization done on the matri-

> ces. For example, transmission rate among those age 0-17 might be underes-303 timated because of restricted attendance in schools. Second, vaccine waning 304 is not considered. However, booster shots are administered and vaccine hes-305 itancy remains low in Korea, which mean that the effect of administered vac-306 cines might be maintained [22]. Third, our age-age matrix focused on the Delta 307 variant, and we were not able to examine transmission of other previous vari-308 ants. The coverage of genomic surveillance among COVID-19 cases in Korea 300 has steadily increased, and it covers about 30% of all confirmed cases. There-310 fore, the number of cases with genomic results before the occurrence of the 311 Delta variant was small to be analyzed separately by variant types. Our result 312 highlighted the transmission pattern of Delta, which is currently the dominant 313 variant in most countries. 314

### **315** 7 Conclusion

This study illustrated the higher transmissibility of the Delta relative to the 316 non-Delta variant among various age groups in Korea by developing the trans-317 mission rate matrix based on MLE. The method used to quantify the effects of 318 the vaccination and NPIs simultaneously. The model simulation results em-319 phasize the importance of simultaneously applying interventions, such as SD, 320 screening measures at the entry points, and vaccination. Another epidemic 321 wave can be avoided if a strict SD policy is not relaxed too early. Transmis-322 sion rate of the Delta variant of COVID-19 is high and oral treatment has not 32 yet been provided widely, but the epidemic is still ongoing, so we suggest that 324 NPIs are still necessary to control the epidemic and reduce the number of se-325 vere cases to prevent a burden to the healthcare system. Even with the same 326 SD level, model simulations showed that outcomes may change depending on 327 vaccine administration and emergence of a highly transmissible variant. If vac-328 cination is slow, then NPIs should be strictly implemented to lessen the medical 329 and socio-economic burden of COVID-19 to the society. 330

### **8** Ethics approval

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Konkuk University (7001355-202101-E-130)

# **335 9 Funding**

This paper is supported by the Korea National Research Foundation (NRF) grant funded by the Korean government (MEST) (NRF-2021M3E5E308120711).

<sup>338</sup> This paper is also supported by the Korea National Research Foundation (NRF)

<sup>339</sup> grant funded by the Korean government (MEST) (NRF-2021R1A2C100448711).

## **Appendix A** Development of the mathematical model

<sup>341</sup> Susceptible individuals in age group *i*, denoted by  $S_i$  (i = 1, 2, ..., 8), who are <sup>342</sup> unvaccinated become exposed to the non-Delta  $E_i^{non\delta}$  or Delta  $E_i^{\delta}$  variants with <sup>343</sup> forces of infection  $\lambda_i^{non\delta}$  or  $\lambda_i^{\delta}$ , respectively. These exposed individuals become <sup>344</sup> infectious  $I_i^{non\delta}$  after  $1/\kappa^{non\delta}$  or  $I_i^{\delta}$  after  $1/\kappa^{\delta}$  days. Here we assume that the <sup>345</sup> latent period of infection with the Delta variant is shorter than the non-Delta <sup>346</sup> variant [23, 24].

To account for vaccination, individuals in  $S_i$  can become effectively  $V_i$  or 347 ineffectively  $U_i$  vaccinated, depending on the daily number of vaccinated in-348 dividuals in age group *i*, denoted by  $v_i$ , and vaccine effectiveness to the non-349 Delta variant  $e_i^{part}$ . Individuals in  $V_i$  eventually become partially  $P_i^{part}$  or fully 350 protected/immune  $P_i^{full}$  from infection after  $1/\omega_i$  days. Fully protected in-351 dividuals are assumed to be immune to COVID-19, while partially protected 352 individuals can only be infected with the Delta variant. Vaccinated individ-353 uals who are exposed to the non-Delta  $E_{i,v}^{non\delta}$  or Delta  $E_{i,v}^{\delta}$  variant eventually 354 progress to the vaccinated infectious classes  $I_{i,v}^{non\delta}$  or  $I_{i,v}^{non\delta}$ . 355

<sup>356</sup> We assume that individuals in the infectious classes  $(I_i^{non\delta}, I_i^{\delta}, I_{i,v}^{non\delta})$  and  $I_{i,v}^{non\delta}$ <sup>357</sup> are isolated as soon as they were confirmed, and are classified as mild  $(Q_i^m, Q_{i,v}^m)$  or severe  $(Q_i^s, Q_{i,v}^s)$ . The mean infectious period of an infected individual <sup>359</sup> is  $1/\alpha$  days, and  $p_i$  or  $p_{i,v}$  denote the proportions that an infected unvaccinated <sup>360</sup> or vaccinated individual progresses to a severe case. Individuals in the isolated <sup>361</sup> compartments recover  $1/\gamma$  days on average and the mean fatality rates of the <sup>362</sup> unvaccinated and vaccinated groups are denoted by  $f_i$  and  $f_{i,v}$ , respectively.

The following system of ordinary differential equations describes the de-

veloped age-structured model:

$$\begin{split} &\frac{dS_{i}}{dt} = -(\lambda_{i}^{non\delta} + \lambda_{i}^{\delta})S_{i} - v_{i}, \\ &\frac{dE_{i}^{non\delta}}{dt} = \lambda_{i}^{non\delta}S_{i} - \kappa^{non\delta}E_{i}^{non\delta}, \quad \frac{dE_{i}^{\delta}}{dt} = \lambda_{i}^{\delta}S_{i} - \kappa^{\delta}E_{i}^{\delta}, \\ &\frac{E_{i,v}^{non\delta}}{dt} = \lambda_{i}^{non\delta}(U_{i} + V_{i}) - \kappa^{non\delta}E_{i}^{non\delta}, \quad \frac{dE_{i,v}^{\delta}}{dt} = \lambda_{i}^{\delta}(U_{i} + V_{i} + P_{i}^{part}) - \kappa^{\delta}E_{i}^{\delta}, \\ &\frac{dI_{i}^{non\delta}}{dt} = \kappa^{\delta}E_{i}^{non\delta} - \alpha I_{i}^{non\delta}, \quad \frac{dI_{i}^{\delta}}{dt} = \kappa^{non\delta}E_{i}^{\delta} - \alpha I_{i}^{\delta}, \\ &\frac{dI_{i,v}^{mon\delta}}{dt} = \kappa^{non\delta}E_{i,v}^{non\delta} - \alpha I_{i,v}^{non\delta}, \quad \frac{dI_{i,v}^{\delta}}{dt} = \kappa^{\delta}E_{i,v}^{\delta} - \alpha I_{i,v}^{\delta}, \\ &\frac{dQ_{i}^{m}}{dt} = \alpha(1 - p_{i})(I_{i}^{non\delta} + I_{i}^{\delta}) - \gamma Q_{i}^{m}, \quad \frac{dQ_{i}^{s}}{dt} = \alpha p_{i}(I_{i}^{non\delta} + I_{i}^{\delta}) - \gamma Q_{i,v}^{s}, \\ &\frac{dQ_{i,v}^{m}}{dt} = \alpha(1 - p_{i,v})(I_{i,v}^{non\delta} + I_{i,v}^{\delta}) - \gamma Q_{i,v}^{m}, \quad \frac{dQ_{i,v}^{s}}{dt} = \alpha p_{i,v}(I_{i,v}^{non\delta} + I_{i,v}^{\delta}) - \gamma Q_{i,v}^{s}, \\ &\frac{dR_{i}}{dt} = \gamma(Q_{i}^{m} + (1 - f_{i})Q_{i}^{s} + Q_{i,v}^{m} + (1 - f_{i,v})Q_{i,v}^{s}), \\ &\frac{dU_{i}}{dt} = (1 - e_{i}^{part})v_{i} - (\lambda_{i}^{non\delta} + \lambda_{i}^{\delta})U_{i}, \\ &\frac{dV_{i}}{dt} = e_{i}^{part}v_{i} - (\lambda_{i}^{non\delta} + \lambda_{i}^{\delta})V_{i} - \omega_{i}V_{i}, \\ &\frac{dP_{i}^{part}}{dt} = \left(1 - \frac{e_{i}^{full}}{e_{i}^{part}}\right)\omega_{i}V_{i} - \lambda_{i}^{\delta}P_{i}^{part}, \\ &\frac{dP_{i}^{full}}{dt} = \frac{e_{i}^{full}}{e_{i}^{part}}\omega_{i}V_{i}, \end{aligned}$$

where the forces of infection  $\lambda_i^{\textit{non}\delta}$  and  $\lambda_i^{\delta}$  are defined as

$$\begin{split} \lambda_i^{non\delta}(t) &= (1-\mu(t)) \sum_{j=1}^8 \beta_{ij}^{non\delta} \frac{I_j^{non\delta} + I_{j,v}^{non\delta}}{N}, \\ \lambda_i^{\delta}(t) &= (1-\mu(t)) \sum_{j=1}^8 \beta_{ij}^{\delta} \frac{I_j^{\delta} + I_{j,v}^{\delta}}{N}, \end{split}$$

 $\mu(t)$  is the phase-dependent, transmission reduction factor accounting for NPIs and its estimated values are in Table 1,  $\beta_{ij}^{non\delta}$  and  $\beta_{ij}^{\delta}$  are the transmission rates

between age groups, and

$$N = \sum_{i=1}^{8} \left( S_i + E_i^{non\delta} + E_i^{\delta} + E_{i,v}^{non\delta} + E_{i,v}^{\delta} + I_i^{non\delta} + I_i^{\delta} + I_{i,v}^{non\delta} + I_{i,v}^{\delta} + R_i + U_i + V_i + P_i^{part} + P_i^{full} \right).$$

Tables 2 and 3 summarize the age-specific and non-age-specific model param-

<sup>364</sup> eters and their values.

| Symbol                 | Description  | Value   | Reference |
|------------------------|--|---------|-----------|
| $1/\kappa^{non\delta}$ | Mean latent period of the non-Delta variant        | 4 days  | [23, 24]  |
| $1/\kappa^{\delta}$    | Mean latent period of the Delta variant            | 2 days  | [23, 24]  |
| 1/α                    | Mean infectious period                             | 6 days  | [24, 25]  |
| $1/\gamma$             | Mean duration of<br>isolation<br>(hospitalization) | 20 days | [26]      |

Table 2: Non-age-specific parameters of the model.

Table 4 shows the vaccine effectiveness of ChAdOx1 and BNT162b2 to the 365 non-Delta and Delta variants after the first and second doses. Table 5 shows 366 the proportion of each age group vaccinated with ChAdOx1, and the calcu-367 lated values of  $e_i^{part}$ ,  $e_i^{full}$  and  $\omega_i$ . The average duration from the first dose to 368 having immunity  $(1/\omega_i)$  and vaccine effectiveness to the non-Delta and Delta 369 variants  $(e_i^{part}, e_i^{full})$  of each age group are calculated depending on the vaccine 370 effectiveness and type of vaccine given to a proportion of an age group. We 371 assume that the interval between doses of ChAdOx1 and BNT152b2 are 11 and 372 4 weeks, respectively. 373

|                       |  |       |      |       | Age g | roup  |       |       |       |
|-----------------------|--|-------|------|-------|-------|-------|-------|-------|-------|
| Symbol Description    |  | 1     | 2    | 3     | 4     | 5     | 6     | 7     | 8     |
| <i>p</i> <sub>i</sub> | Proportion of<br>unvaccinated<br>group <i>i</i> that<br>becomes severe | 0     | 0    | 0.01  | 0.02  | 0.04  | 0.07  | 0.13  | 0.26  |
| p <sub>i,v</sub>      | Proportion of<br>vaccinated group <i>i</i><br>that becomes<br>severe   | 0     | 0    | 0     | 0.01  | 0.01  | 0.03  | 0.02  | 0.05  |
| $f_i$                 | Mean fatality rate<br>of unvaccinated<br>group <i>i</i> (1/day)        | 0     | 0    | 0     | 0     | 0     | 0.01  | 0.03  | 0.13  |
| f <sub>i,v</sub>      | Mean fatality rate<br>of vaccinated<br>group <i>i</i> (1/day)          | 0     | 0    | 0     | 0     | 0     | 0     | 0     | 0.01  |
| $e_i^{part}$          | Vaccine<br>effectiveness to<br>non-Delta                               | 0.94  | 0.93 | 0.91  | 0.9   | 0.91  | 0.76  | 0.83  | 0.92  |
| $e_i^{full}$          | Vaccine<br>effectiveness to<br>Delta                                   | 0.88  | 0.87 | 0.85  | 0.84  | 0.85  | 0.69  | 0.76  | 0.86  |
| $1/\omega_i$          | Mean interval from<br>first dose to<br>immunity (1/day)                | 35.44 | 36.4 | 40.12 | 41.91 | 39.44 | 64.08 | 52.52 | 38.95 |

Table 3: Age-specific parameters of the model calculated using data from [10, 11] and vaccine effectiveness summarized in Table 4.

|  | ChA           | dOx1           | BNT162b2      |                |  |
|--|---------------|----------------|---------------|----------------|--|
|  | First<br>dose | Second<br>dose | First<br>dose | Second<br>dose |  |
| Vaccine effectiveness to the non-Delta variant | 0.49          | 0.74           | 0.47          | 0.94           |  |
| Vaccine effectiveness to the Delta variant     | 0.30          | 0.67           | 0.36          | 0.88           |  |

Table 4: Vaccine effectiveness of ChAdOx1 and BNT162b2 to the non-Delta and Delta variants depending on the number of doses [3].

|  | Age group |       |       |       |       |       |       |       |
|--|-----------|-------|-------|-------|-------|-------|-------|-------|
| Description  | 1         | 2     | 3     | 4     | 5     | 6     | 7     | 8     |
| Proportion of age<br>group <i>i</i> administered<br>with ChAdOx1 | 0.00      | 0.03  | 0.15  | 0.21  | 0.13  | 0.93  | 0.55  | 0.11  |
| $e_i^{part}$   | 0.94      | 0.93  | 0.91  | 0.9   | 0.91  | 0.76  | 0.83  | 0.92  |
| $e_i^{full}$   | 0.88      | 0.87  | 0.85  | 0.84  | 0.85  | 0.69  | 0.76  | 0.86  |
| $1/\omega_i$ (days)  | 35.44     | 36.40 | 40.12 | 41.91 | 39.44 | 64.08 | 52.52 | 38.95 |

Table 5: Proportion of age group *i* administered with ChAdOx1 from data [10] and the calculated age-dependent vaccine effectiveness to the Delta and non-Delta variants, and average duration to develop full immunity.

## <sup>374</sup> Appendix B MLE formulation

To establish the likelihood function to be optimized, we first divide each age group into three subgroups to distinguish COVID-19 outcomes: infected ( $\Lambda_{Ii}$ ), unvaccinated and uninfected ( $\Lambda_{Si}$ ), and effectively vaccinated and uninfected ( $\Lambda_{Vi}$ ), where *i* indicates the age group. Let  $\beta_{XY}$  be the transmission rate from age group *Y* to *X*. Assuming a homogeneous mixing of the population, and that the transmission events are exponentially distributed, the probability that an individual *x* in subgroup  $\Lambda$  at the time t - 1 is still uninfected until the next time *t* is given by

$$p_{S,\Lambda,x}(t) = exp\left(-\frac{\sum_j \beta_{ij}\mathbf{I}_j(t-1)}{N}\right),$$

where  $I_j(t-1)$  denotes the number of hosts in group *j* which can spread the disease at time t - 1, and *N* is the total population. We can set *N* as a constant because the number of isolated individuals (or deceased) is less than 0.02% of the population. On the other hand, the probability that an individual *x* in

group  $\Lambda$  is uninfected at the time t - 1 but becomes infected at t is

$$p_{I,\Lambda,x}(t) = 1 - exp\left(-\frac{\sum \beta_{ij}\mathbf{I}_j(t-1)}{N}\right)$$

Hence, an individual who stays uninfected until final time  $t_f$  has probabilities  $p_{S,\Lambda,x}(t)$  at each time until  $t_f$ . In addition, an individual can be vaccinated at time  $t_{Vi,x}$ , have immunity after  $t_{e,i}$  days, and stay uninfected until final time  $t_f$ . An individual infected at time  $t_{Ii,x}$  has probabilities  $p_{S,\Lambda,x}(t)$  until  $t_{Ii,x} - 1$  and  $p_{Ii,\Lambda,x}(t_{Ii,x})$ .

The likelihood function L is formulated as

$$L = \prod_{i} \left( L_{1,i} \cdot L_{2,i} \cdot L_{3,i} \right),$$

where

$$L_{1,i} = \prod_{x \in \Lambda_{Si}} \left( \prod_{t=0}^{t_f} p_{Si,x}(t) \right),$$
  

$$L_{2,i} = \prod_{x \in \Lambda_{Vi}} \left( \prod_{t=0}^{\min\{t_f, t_{Vi,x} + t_{e,i}\}} p_{S,\Lambda_{Vi},x}(t) \right),$$
  

$$L_{3,i} = \prod_{x \in \Lambda_{Ii}} \left( \prod_{t=0}^{t_{Ii,x}-1} p_{S,\Lambda_{Ii},x}(t) \right) p_{I,\Lambda_{Ii},x}(t_{Ii,x}).$$

<sup>385</sup> By taking the logarithm of *L* and using the optimization toolbox in MATLAB,

we obtain a matrix containing the transmission rates of the Delta and non-Delta

<sup>387</sup> variants between age groups.

# Appendix C Normalized transmission rate matrices and the effective reproductive number

<sup>390</sup> Let the transmission rate matrices estimated from 26 February to 30 June and

<sup>391</sup> from 01 August to 10 September be  $M_{est}^{non\delta}$  and  $M_{est}^{\delta}$ , respectively. First, the re-

<sup>392</sup> productive number of COVID-19 using  $M_{est}^{non\delta}$  is calculated via the next-generation-

matrix method and denoted as  $\mathcal{R}_{est}^{non\delta}$ . Second, a normalized transmission rate

<sup>394</sup> matrix of the non-Delta variant,  $M^{non\delta}$ , is formulated as  $M^{non\delta} = M_{est}^{non\delta} \mathcal{R}_0^{non\delta} / \mathcal{R}_{est}^{non\delta}$ ,

<sup>395</sup> where  $\mathcal{R}_0^{non\delta}$ , equal to 3.17, is the basic reproductive number of COVID-19 esti-

<sup>396</sup> mated from various studies before Delta variant became the major strain [27].

Third, a normalized transmission rate matrix of the Delta variant is formulated similarly as  $M^{\delta} = M_{est}^{\delta} \mathcal{R}_{0}^{\delta} / \mathcal{R}_{est}^{\delta}$ , where  $\mathcal{R}_{0}^{\delta}$  is reproductive number calculated using  $M_{est}^{\delta}$  and  $\mathcal{R}_{0}^{\delta} = 1.97 \mathcal{R}_{0}^{non\delta}$  [28]. The normalized transmission rate matrices,  $M^{non\delta}$  and  $M^{\delta}$ , are used in this research.

The effective reproductive number  $\mathcal{R}_t$  is a time-dependent measure of the average number of secondary cases from a single infectious individual [29]. In this study,  $\mathcal{R}_t$  is calculated using the next-generation matrix method [30]. Using the normalized transmission rate matrices,  $\mathcal{R}_t$  of the non-Delta and Delta variants are 3.17 and 6.24, respectively, if there are no NPIs and behavior change.

### **References**

[1] Lianlian Bian, Qiushuang Gao, Fan Gao, Qian Wang, Qian He, Xing Wu,

408 Qunying Mao, Miao Xu, and Zhenglun Liang. Impact of the delta vari-

<sup>409</sup> ant on vaccine efficacy and response strategies. *Expert Review of Vaccines*,

410 0(0):1–9, 2021. PMID: 34488546.

- [2] WHO Situation Reports. https://www.who.int/publications/m/item/
- 412 weekly-epidemiological-update-on-covid-19---5-october-2021.
- 413 Accessed: October 6, 2021.
- [3] Jamie Lopez Bernal, Nick Andrews, Charlotte Gower, Eileen Gallagher,
  Ruth Simmons, Simon Thelwall, Julia Stowe, Elise Tessier, Natalie Groves,
  Gavin Dabrera, et al. Effectiveness of covid-19 vaccines against the b.
  1.617. 2 (delta) variant. *N Engl J Med*, pages 585–594, 2021.
- [4] Centers for Disease Control and Prevention, National Center for
  Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases, U.S. Science Brief: COVID-19 Vaccines and Vaccination. https://www.cdc.gov/coronavirus/2019-ncov/science/
  science-briefs/fully-vaccinated-people.html. Accessed: October 6,
  2021.
- [5] Ministry of Health and Welfare, Republic of Korea. Coronavirus disease
   2019 (COVID-19). http://ncov.mohw.go.kr/en/. Accessed: October 6,
   2021.
- [6] Korea Disease Control and Prevention Agency; Proportions of variants
   among sampled genome sequencing in Korea. https://kdca.go.kr/
   contents.es?mid=a20107040000. Accessed: October 27, 2021.
- [7] Youngsuk Ko, Jacob Lee, Yeonju Kim, Donghyok Kwon, and Eunok Jung.
   COVID-19 Vaccine Priority Strategy Using a Heterogenous Transmission
   Model Based on Maximum Likelihood Estimation in the Republic of Ko rea. International Journal of Environmental Research and Public Health, 18(12),
   2021.

- [8] Youngsuk Ko, Jacob Lee, Yubin Seo, and Eunok Jung. Risk of COVID-19
- transmission in heterogeneous age groups and effective vaccination strategy in Korea: A mathematical modeling study. *EpiH*, 2021.
- [9] Korea Disease Control and Prevention Agency; Who will have vaccine
- first? https://ncv.kdca.go.kr/menu.es?mid=a10117010000. Accessed:
   October 14, 2021.
- [10] Korea Disease Control and Prevention Agency; Korean situation report
- of COVID-19; 2021 October 8. http://ncov.mohw.go.kr/tcmBoardView.
- do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=5989&contSeq=

5989&board\_id=312&gubun=ALL. Accessed: October 14, 2021.

- [11] Korea Disease Control and Prevention Agency, Questions and answers
  about COVID-19 vaccines, criteria for the implementation of COVID-19
  vaccination. https://ncv.kdca.go.kr/menu.es?mid=a12207000000. Accessed: October 14, 2021.
- [12] YTN science, Delta variant takes 96.7% among variants and number of cases for a week was 2555, 7467 in total. https: //science.ytn.co.kr/program/program\_view.php?s\_mcd=0082&key= 202108101604183996&page=2. Accessed: October 14, 2021.
- [13] National Institute for Mathematical Sciences, COVID-19 forecasts us ing mathematical modeling. https://www.nims.re.kr/research/post/
   covid19\_2/34405. Accessed: October 14, 2021.
- [14] The Ministry of Health and Welfare, Plan of the step-by-step recovery
   from COVID-19. http://www.mohw.go.kr/react/al/sal0301vw.jsp?
   PAR\_MENU\_ID=04&MENU\_ID=0403&page=1&CONT\_SEQ=368237. Accessed:
   October 14, 2021.

- [15] Kim Youngwha, Kim Yuyeon, Hansol Yum, Jinwha Jang, Inseop Hwang,
- 461 Gwangsuk Park, Youngjun Park, Sangwon Lee, and Donghyeok Kwon.
- Annual covid-19 occurrence report. *Korea Disease Control and Prevention*
- Agency: Weekly health and diseases, 14(9), 2021.
- <sup>464</sup> [16] Korea Disease Control and Prevention Agency; Korean situation report of
- 465 COVID-19; 2021 October 27. http://ncov.mohw.go.kr/tcmBoardView.
- do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=6043&contSeq=
- <sup>467</sup> 6043&board\_id=312&gubun=ALL. Accessed: October 27, 2021.
- [17] Kendra Dougherty, Mike Mannell, Ozair Naqvi, Dakota Matson, and Jolianne Stone. Sars-cov-2 b. 1.617. 2 (delta) variant covid-19 outbreak associated with a gymnastics facility—oklahoma, april–may 2021. *Morbidity and Mortality Weekly Report*, 70(28):1004, 2021.
- [18] Elisabeth Mahase. Delta variant: What is happening with transmission,
  hospital admissions, and restrictions?, 2021.
- [19] Ministry of Education, Announce about school operation plan after
  Chuseok holiday. https://www.korea.kr/news/policyNewsView.do?
  newsId=148878606. Accessed: October 14, 2021.
- [20] Jinhwa Jang, Myung-Jae Hwang, Shin Young Park, Seong-Sun Kim,
  Jemma Park, Hansol Yeom, Su Bin Park, and Kwon Donghyoks. Trends in
  covid-19 cases among children and adolescents aged 0-18 years in the republic of korea. *Korea Disease Control and Prevention Agency: Weekly health*and diseases, 14(42), 2021.
- [21] Korea Disease Control and Prevention Agency, Anounce about
   the adjustement of social distancing. http://ncov.mohw.go.kr/
   infoBoardView.do?brdId=3&brdGubun=32&dataGubun=&ncvContSeq=
- 6009&contSeq=6009&board\_id=&gubun=. Accessed: October 14, 2021.

<sup>486</sup> [22] Hyun Kyung Park, Ji Hye Ham, Deok Hyun Jang, Jin Yong Lee, and

- Won Mo Jang. Political ideologies, government trust, and covid-19 vac cine hesitancy in south korea: A cross-sectional survey. *International Jour- nal of Environmental Research and Public Health*, 18(20):10655, 2021.
- [23] Yaping Wang, Ruchong Chen, Fengyu Hu, Yun Lan, Zhaowei Yang, Chen
   Zhan, Jingrong Shi, Xizi Deng, Mei Jiang, Shuxin Zhong, et al. Transmission, viral kinetics and clinical characteristics of the emergent sars-cov-2
   delta voc in guangzhou, china. *EClinicalMedicine*, 40:101129, 2021.
- <sup>494</sup> [24] World Health Organization et al. Transmission of sars-cov-2: implications
   <sup>495</sup> for infection prevention precautions: scientific brief, 09 july 2020. Techni <sup>496</sup> cal report, World Health Organization, 2020.
- <sup>497</sup> [25] Moran Ki et al. Epidemiologic characteristics of early cases with 2019
   <sup>498</sup> novel coronavirus (2019-ncov) disease in korea. *Epidemiology and health*,
   <sup>499</sup> 42, 2020.
- [26] Yong-Hoon Lee, Chae Moon Hong, Dae Hyun Kim, Taek Hoo Lee, and
   Jaetae Lee. Clinical course of asymptomatic and mildly symptomatic pa tients with coronavirus disease admitted to community treatment centers,
   south korea. *Emerging infectious diseases*, 26(10):2346, 2020.
- [27] Md Arif Billah, Md Mamun Miah, and Md Nuruzzaman Khan. Repro ductive number of coronavirus: A systematic review and meta-analysis
   based on global level evidence. *PloS one*, 15(11):e0242128, 2020.

[28] Finlay Campbell, Brett Archer, Henry Laurenson-Schafer, Yuka Jinnai,
 Franck Konings, Neale Batra, Boris Pavlin, Katelijn Vandemaele, Maria D
 Van Kerkhove, Thibaut Jombart, et al. Increased transmissibility and
 global spread of sars-cov-2 variants of concern as at june 2021. *Eurosurveil- lance*, 26(24):2100509, 2021.

- 512 [29] Hiroshi Nishiura and Gerardo Chowell. The Effective Reproduction Number
- as a Prelude to Statistical Estimation of Time-Dependent Epidemic Trends, pages
- <sup>514</sup> 103–121. Springer Netherlands, Dordrecht, 2009.
- 515 [30] Odo Diekmann, JAP Heesterbeek, and Michael G Roberts. The con-
- struction of next-generation matrices for compartmental epidemic mod-
- els. Journal of the Royal Society Interface, 7(47):873–885, 2010.





medRxiv preprint doi: https://doi.org/10.1101/2021.11.01.21265729; this version posted November 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.









